What's New

Last Posted: Oct 04, 2024

• Reduced platelet activation in triple-negative essential thrombocythemia compared with JAK2V617F-mutated essential thrombocythemia.
  Huan Dong, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 0
• Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.
  Pirun Saelue, et al. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024 0 10760296241263099
• Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.
  Keiki Nagaharu, et al. Annals of hematology 2024 0
• Clonal evolution process from essential thrombocythemia to acute myeloid leukemia in the original patient from whom the CALR-mutated Marimo cell line was established.
  Yoko Ushijima, et al. Nagoya journal of medical science 2024 0 (2) 326-332
• [Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].
  Min Wang, et al. Zhongguo shi yan xue ye xue za zhi 2024 0 (3) 819-824
• Raman Spectroscopy of Blood Serum for Essential Thrombocythemia Diagnosis: Correlation with Genetic Mutations and Optimization of Laser Wavelengths.
  Aynur Aday, et al. Cell biochemistry and biophysics 2024 0
• Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms.
  Shirong Wen, et al. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2024 0 159-166
• Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.
  Jhemerson F Paes, et al. Scientific reports 2024 0 (1) 9389
• Sex-specific impact on disease outcome and the mutational landscape in essential thrombocythemia: A retrospective cohort study.
  Jia Chen, et al. Chinese medical journal 2024 0
• Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
  Marta Garrote, et al. Annals of hematology 2024 0
• CALR mutation burden in essential thrombocythemia and disease outcome.
  Paola Guglielmelli, et al. Blood 2024 0
• One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
  Giuseppe G Loscocco, et al. Blood cancer journal 2024 0 (1) 10
• One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
  Naseema Gangat, et al. Blood cancer journal 2024 0 (1) 11
• JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
  Ana Isabel Giraldo-Rincón, et al. Colombia medica (Cali, Colombia) 2023 0 (3) e2035353
• Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative Neoplasms.
  Hiroki Hosoi, et al. Internal medicine (Tokyo, Japan) 2023 0
• Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil.
  Dania G Torres, et al. Biomedical reports 2023 0 (6) 98
• The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype.
  Patryk Sobieralski, et al. Frontiers in oncology 2023 0 1224590
• The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.
  Helna Pettersson, et al. Frontiers in oncology 2023 0 1190305
• The Clinical Impact of JAK2V617F allele burden in Philadelphia-negative Myeloproliferative Neoplasms.
  ?pek Yönal-Hindilerden, et al. Turkish journal of haematology : official journal of Turkish Society of Haematology 2023 0
• Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
  Marta Garrote, et al. Cancers 2023 0 (15)
• Expression properties, structural features and functional analysis of CALR E381A in MPN patients.
  Kaihong Xu, et al. American journal of translational research 2023 0 (7) 4718-4726
• Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
  Jin Zhang, et al. Frontiers in genetics 2023 0 1198834
• MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan.
  Chiho Furuya, et al. Hematology (Amsterdam, Netherlands) 2023 0 (1) 2229131
• [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
  X Yan, et al. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2023 0 (4) 276-283
• Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.
  Rongfeng Fu, et al. Annals of hematology 2023 0
• JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
  Mohamed Hussam Aswad, et al. Clinical hemorheology and microcirculation 2023 0
• Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.
  It?r ?irino?lu Demiriz, et al. Molecular biology reports 2023 0
• Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
  Sun?ica Kapor, et al. Advances in experimental medicine and biology 2023 0 273-290
• JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients.
  Shires Karen L, et al. Hematology/oncology and stem cell therapy 2023 0 (3) 303-314
• Clinical and molecular characteristics of forty Chinese children with essential thrombocythemia: A single-center, retrospective analysis.
  Zhang Luyang, et al. British journal of haematology 2023 0
• Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.
  Kuo Ming-Chung, et al. American journal of clinical pathology 2023 0
• Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL.
  Wang Yan, et al. Technology in cancer research & treatment 2023 0 15330338231154092
• Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
  Aldea Mihaela, et al. JCO precision oncology 2023 0 e2200583
• The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
  Basim Najm Maysam, et al. Cellular and molecular biology (Noisy-le-Grand, France) 2023 0 (8) 202-209
• Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
  Rumi Elisa, et al. Oncotarget 2017 0 (60) 101735-101744
• High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
  Castelli Roberto, et al. Journal of thrombosis and thrombolysis 2017 0 (1) 106-113
• Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
  Senín Alicia, et al. Annals of hematology 2017 0 (3) 443-451
• Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort.
  Puyade Mathieu, et al. Obstetric medicine 2017 0 (4) 165-169
• Genetic Risk Assessment in Myeloproliferative Neoplasms.
  Tefferi Ayalew, et al. Mayo Clinic proceedings 2017 0 (8) 1283-1290
• [Variation of STAT3 Gene in Myleproliferative Neoplasms and Its Significance].
  Tan Mei, et al. Zhongguo shi yan xue ye xue za zhi 2018 0 (5) 1430-1436
• A triplex probe-based TaqMan qPCR assay for Calreticulin type I and II mutation detection.
  Tang Yigui, et al. Hematology (Amsterdam, Netherlands) 2018 0 (1) 26-31
• Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
  Grinfeld Jacob, et al. The New England journal of medicine 2018 0 (15) 1416-1430
• Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
  Horvat Ivana, et al. Clinical lymphoma, myeloma & leukemia 2018 0 (1) 53-63
• Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
  Zhou Dian, et al. Leukemia research 2018 0 1-6
• Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
  Hashimoto Yoshinori, et al. European journal of haematology 2018 0 (4) 508-513
• A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia.
  Lee Jee-Soo, et al. Laboratory medicine 2019 0 (3) 306-309
• JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
  Patel Ami B, et al. Blood 2019 0 (26) 2388-2398
• Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-characteristics along with a validation of 2016 WHO criteria.
  Sobieralski Patryk, et al. European journal of haematology 2019 0 (6) 558-563
• Mutational profiling in myelofibrosis: implications for management.
  Bose Prithviraj, et al. International journal of hematology 2019 0 (2) 192-199
• Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
  Yacoub Abdulraheem, et al. Blood 2019 0 (18) 1498-1509

More